Smith & Nephew plc vs Toyota Motor Corp — how do they compare? Smith & Nephew plc trades at $30.05 (market cap $12.50B), while Toyota Motor Corp trades at $187.62 (market cap $223.57B). The key difference: Toyota Motor Corp is far larger — about 17.9× Smith & Nephew plc's market cap, and Toyota Motor Corp pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| SNN | TM | |
|---|---|---|
Market Cap | $12.50B | $223.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $38.70 | $248.29 |
52-Week Low | $28.73 | $166.50 |
Enterprise Value | $15.53B | $417.39B |
Dividend Yield | 2.64% | 3.32% |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.
The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.
Toyota Motor (TM) trades at $190.09, up 1.39% with bullish technical signals and strong fundamentals. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $7.57 exceeding expectations by 62%. Valuation remains attractive with P/E of 8.48 and P/B of 0.95, while revenue growth continues at $48.04T for 2025. Technical indicators show bullish moving averages and support at $189.
Outlook remains positive given strong hybrid vehicle demand and raised earnings guidance, though risks include China sales weakness and recall-related costs. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations. The stock presents value opportunity with solid cash flow generation and market leadership position.
Trailing returns across standard periods
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →